Similarly, emerging IL‐6 receptor antagonists, such as tocilizumab and novel anti‐hepcidin agents, have shown promise in chronic kidney disease and rheumatoid arthritis for improving haemoglobin, warranting exploration in obesity‐related anaemia [31]. The gene discussed is HAMP; the disease is rheumatoid arthritis.